A phase 2, double-blind, placebo-controlled trial of a valproate/lithium combination in ALS patients
Background: Few treatments are currently available for amyotrophic lateral sclerosis (ALS). A combination of lithium carbonate and valproic acid (VPA-Li) was shown to inhibit motor neuron death and delay disease progression. Methods: Outpatients with a typical ALS presentation were enrolled in a ran...
Saved in:
Main Authors: | M.-C. Boll, M. Alcaraz-Zubeldia, C. Rios, D. González-Esquivel, S. Montes |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier España
2025-01-01
|
Series: | Neurología (English Edition) |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S217358082200089X |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
by: Leslie Pérez Ruiz, et al.
Published: (2007-12-01) -
Adverse Reactions due to the Usage Ofadverse Effects due to the Usage of T biomodulina and corticotropin in Patients Suffering from Multiple Sclerosis
by: Rosa F. Lara Rodríguez, et al.
Published: (2007-05-01) -
Uma carta para Mark Freeman sobre a “promessa trágica” de doenças neurodegenerativas
by: Will Lucas Silva Pena
Published: (2021-05-01) -
Preventive vaccines for COVID-19. An expectant reality
by: Ana María Ramos Cedeño, et al.
Published: (2020-11-01) -
Hipertensión arterial refractaria y la espironolactona. Análisis del ensayo clínico PATHWAY 2
by: Alberto Morales Salinas, et al.
Published: (2016-09-01)